Roche's Polivy (polatuzumab vedotin) Receives Health Canada's Approval For R/R Diffuse Large B Cell Lymphoma
Shots:
- Health Canada- under (NOC/c) policy- has granted market authorization to Polivy + bendamustine and rituximab (BR) for six 21-day cycles in adult patients with r/r DLBCL- who are not eligible for ASCT and prior treated with at least one therapy
- The approval is based on P-I/II GO29365 study assessing Polivy + BR vs BR alone in 80 patients- including 4 Canadians with previously treated DLBCL. Results: patients achieving CR or PR (40% vs 18%); mDoR (12.6 vs 7.7mos.)
- Polivy is an ADC- targeting CD79b and destroys the B cells through the delivery of an anti-cancer agent- while minimizing the effects on normal cells
Ref: PRNewswire | Image: Roche
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com